Palatine’s Impact Fund backs tranScrip
Palatine Private Equity has completed the seventh investment from its Impact Fund, with the acquisition of a significant minority stake in tranScrip, a fast-growing global business playing a key role in the innovation and commercialisation of new medicines, including treatments for Covid-19. Headquartered in the Thames Valley, tranScrip provides a
